Obagi Medical Products (OMPI) Discontinues Distribution in the Pharmacy Channel
More News related to OMPI
- Canaccord Adams Maintains a 'Buy' on Obagi Medical Products (OMPI); Raises PT
- OBAGI Medical (OMPI) Posts Q3 EPS of $0.14, In-Line with Street; Guides
- Obagi Medical Products Reports Third Quarter 2009 Earnings
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Obagi Medical Products to Report Third Quarter 2009 Financial Results and Host a Conference Call on November 5, 2009
More News related to Corporate News
- Pike Electric (PIKE) Misses Views, Posts Q3 Loss of 8c
- Clean Energy Fuels (CLNE) Misses Q3 EPS by 1c
- Emeritus Corp. (ESC) Posts Q3 Loss of $0.41, Misses Views
- HQ Sustainable Maritime (HQS) Posts Q3 EPS of $0.26, Tops by 1c
- Infinity Pharma (INFI) Posts Q3 Loss of 36c, Beats Eatimates by 8c
Obagi Medical Products, Inc. (NASDAQ: OMPI) announced that it has ceased selling SoluCLENZ Rx Gel(TM) which had been sold through pharmacies since August 2008.
"Our patented solubilized benzoyl peroxide (BPO) technology that is in our acne product lines has been shown to provide an enhanced efficacy profile compared to the leading BPO/antibiotic combination acne product in more than 15 clinical studies and publications. This novel BPO technology has drawn the interest and product adoption of key opinion leaders and top acne prescribing dermatologists as evidenced by the success of the Obagi CLENZIderm(R) M.D. brand in the physician-dispense channel," said Steve Carlson, President and CEO.
Related Categories
Corporate NewsStocks Mentioned
+0.21Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
